Amicus Briefs

BIO filed an amicus brief July 19 in the case of Bristol Meyers Squibb and Janssen, who are appealing a decision by the U.S. District Court for the District of New Jersey. The companies argue that the Inflation Reduction Act (IRA) drug…

The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge the Federal Trade Commission (FTC) lawsuit to block the acquisition of Horizon by Amgen. The amicus brief was filed in the U.S. District Court, Northern…

The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge a District Court’s unprecedented ruling (related to a single drug known as mifepristone) that would create regulatory barriers and potentially upend FDA’s…

BIO has filed an amicus brief in U.S. ex rel. Scutte v. SuperValu Inc., which addresses the issue of the intent requirement under the False Claims Act (FCA). Specifically, BIO urges the Court to uphold the view that a firm does not…

BIO and AUTM have filed an amicus brief in petition for a writ of certiorari the in American Axle & Manufacturing, Inc., v. Neapco Holdings LLC, et al., at the Supreme Court of the United States. BIO and AUTM are concerned that…

BIO files amicus brief in support of a petition for rehearing related to patent-eligibility of diagnostic technology. 

BIO files an Amicus Brief on rehearing by the Precedential Opinion Panel of the Patent Trial and Appeal Board.

Natural Alternatives International v. Creative Compounds (BIO Brief as Amicus Curiae supporting appellant in the US Court of Appeals for the Federal Circuit)

BIO and PhRMA have submitted a brief in the U.S Court of Appeals for the Federal Circuit on behalf of appellant in Virnetx Inc. v. The Mangrove Partners. 

BIO submitted an amicus brief in the U.S. Court of Appeals for the Federal Circuit, supporting Acorda Therapeutics and reversal.